Loading...
Loading...
Novartis has agreed to acquire Myricx Bio, a UK-based biotech company specializing in cancer medicines. The deal is valued at up to $1.5 billion. Myricx Bio investor Sofinnova Partners announced the acquisition. The purchase adds a British start-up focused on cancer drugs to Novartis.
by WorldBrief & Maksim Micheliov | AI-generated summary
A wrong detail, a missing source, or an event on the wrong conflict? Tell me. I read everything.
6 headlines from 6 publishers

